Nyrada Inc (NYR) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.453x

Based on the latest financial reports, Nyrada Inc (NYR) has a cash flow conversion efficiency ratio of -0.453x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-4.46 Million ≈ $-3.16 Million USD) by net assets (AU$9.84 Million ≈ $6.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Nyrada Inc - Cash Flow Conversion Efficiency Trend (2018–2025)

This chart illustrates how Nyrada Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read NYR current and long-term liabilities for a breakdown of total debt and financial obligations.

Nyrada Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Nyrada Inc ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Jeil Pharm
KO:002620
0.031x
Dual Co Ltd
KO:016740
0.028x
BJ.B.J.B.UNI.S.(NEW)YC-10
F:BJDH
N/A
Highlight Event Entertainment
SW:HLEE
0.226x
ULMA Construccion Polska SA
WAR:ULM
0.002x
Astro Malaysia Holdings Bhd
KLSE:6399
0.127x
ÖKOWORLD AG
XETRA:VVV3
0.008x
EPE Capital Partners Ltd
JSE:EPE
0.002x

Annual Cash Flow Conversion Efficiency for Nyrada Inc (2018–2025)

The table below shows the annual cash flow conversion efficiency of Nyrada Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see NYR market cap.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$3.58 Million
≈ $2.53 Million
AU$-5.05 Million
≈ $-3.57 Million
-1.412x -831.05%
2024-06-30 AU$5.05 Million
≈ $3.57 Million
AU$-766.29K
≈ $-542.20K
-0.152x +91.07%
2023-06-30 AU$4.26 Million
≈ $3.01 Million
AU$-7.23 Million
≈ $-5.12 Million
-1.698x -565.58%
2022-06-30 AU$11.50 Million
≈ $8.14 Million
AU$-2.93 Million
≈ $-2.08 Million
-0.255x -33.34%
2021-06-30 AU$14.49 Million
≈ $10.25 Million
AU$-2.77 Million
≈ $-1.96 Million
-0.191x +76.02%
2020-06-30 AU$5.53 Million
≈ $3.91 Million
AU$-4.41 Million
≈ $-3.12 Million
-0.798x -297.19%
2019-06-30 AU$-4.95 Million
≈ $-3.51 Million
AU$-2.01 Million
≈ $-1.42 Million
0.405x -20.09%
2018-06-30 AU$-1.36 Million
≈ $-964.18K
AU$-690.18K
≈ $-488.35K
0.506x --

About Nyrada Inc

AU:NYR Australia Biotechnology
Market Cap
$91.86 Million
AU$129.82 Million AUD
Market Cap Rank
#19515 Global
#645 in Australia
Share Price
AU$0.53
Change (1 day)
-7.02%
52-Week Range
AU$0.10 - AU$1.38
All Time High
AU$1.38
About

Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporat… Read more